Safety of measles-containing vaccines in 1-year-old children

Pediatrics

Volumn 135, Issue 2, 2015, Pages e321-e329

  Klein, Nicola P ^a   Lewis, Edwin ^a   Fireman, Bruce ^a   Hambidge, Simon J ^b   Naleway, Allison ^c   Nelson, Jennifer C ^d   Belongia, Edward A ^e   Yi, Katherine W ^f   Nordin, James D ^g   Hechter, Rulin C ^a   Weintrau, Eric ^h   Baxter, Roger ^a  

^a KAISER PERMANENTE   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MARSHFIELD CLINIC   (United States)

^f HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^g HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE; PHARMACOLOGICAL BIOMARKER; VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ATAXIA; ATTRIBUTABLE RISK; CHILD; DRUG SAFETY; FEVER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL HISTORY; MENINGITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; RISK; RISK ASSESSMENT; SEIZURE; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; FEBRILE CONVULSION; FEMALE; INFANT; MALE; UNITED STATES;

BIOMARKERS, PHARMACOLOGICAL; CHICKENPOX VACCINE; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; RISK ASSESSMENT; SEIZURES, FEBRILE; UNITED STATES; VACCINES, COMBINED;

EID: 84922639848     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-1822     Document Type: Article

References (44)

1. Barlow WE, Davis RL, Glasser JW, et al Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345(9):656-661
2. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567-569
3. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991;88(5):881-885
4. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292(3):351-357
5. Lieberman JM, Williams WR, Miller JM, et al; Consistency Lot Study Group for ProQuad. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006;25(7):615-622
6. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665-669
7. Shinefield H, Black S, Thear M, et al; 013 Study Group for ProQuad. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006;25(4):287-292
8. France EK, Glanz J, Xu S, et al; Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121(3). Available at: www.pediatrics.org/cgi/content/full/121/3/e687
9. Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a casecontrol study in Italy. Drug Saf. 2010;33(1):65-72
10. O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129(2):248-255
11. Bohlke K, Davis RL, Marcy SM, et al; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-820
12. Carapetis JR, Curtis N, Royle J. MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare. BMJ. 2001;323(7317):869
13. Pool V, Braun MM, Kelso JM, et al; VAERS Team. US Vaccine Adverse Event Reporting System. Prevalence of antigelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2002;110(6). Available at: www.pediatrics.org/cgi/content/full/110/6/e71
14. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press; 2011
15. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 2006;55(RR-15):1-48
16. Belongia EA, Irving SA, Shui IM, et al; Vaccine Safety Datalink Investigation Group. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010;29(1):1-5
17. Lieu TA, Kulldorff M, Davis RL, et al; Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 suppl 2):S89-S95
18. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57(10):258-260
19. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656-4661
20. Klein NP, Fireman B, Yih WK, et al; Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1). Available at: www.pediatrics.org/cgi/content/full/126/1/e1
21. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12
22. Klein NP, Lewis E, Baxter R, et al. Measlescontaining vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809-814
23. Rowhani-Rahbar A, Klein NP, Dekker CL, et al; Risk Interval Working Group of the Clinical Immunization Safety Assessment Network. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012;31(1):271-277
24. Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for prespecified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31(22):2578-2583
25. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-8284
26. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140-1148
27. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. Vaccine. 2012;30(20):3053-3060
28. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine. 2012;30(19):2989-2998
29. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170(5):650-656
30. Rowhani-Rahbar A, Klein NP, Lewis N, et al. Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012;175(9):878-885
31. Baxter R, Bakshi N, Fireman B, Lewis E, Ray P, Vellozzi C, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013;57(2):197-204
32. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209-212
33. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873-890
34. Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645-650
35. Hambidge SJ, Newcomer SR, Narwaney KJ, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014;133(6). Available at: www.pediatrics.org/cgi/content/full/133/6/e1492
36. MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ. 2014;186(11):824-829
37. Plesner AM, Hansen FJ, Taudorf K, Nielsen LH, Larsen CB, Pedersen E. Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. Acta Paediatr. 2000;89(1):58-63
38. Miller E, Andrews N, Grant A, Stowe J, Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Arch Dis Child. 2005;90(3):292-296
39. van der Maas NA, Bondt PE, de Melker H, Kemmeren JM. Acute cerebellar ataxia in the Netherlands: a study on the association with vaccinations and varicella zoster infection. Vaccine. 2009;27(13):1970-1973
40. Rack AL, Grote V, Streng A, et al. Neurologic varicella complications before routine immunization in Germany. Pediatr Neurol. 2010;42(1):40-48
41. Kuter BJ, Brown ML, Hartzel J, et al; Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2(5):205-214
42. Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012;30(26):3929-3936
43. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012;31(8):e133-e140
44. Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013;167(12):1111-1117